Cargando…
Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures
SIMPLE SUMMARY: Currently available biomarkers for response to checkpoint inhibitors are incomplete and predominantly focus on tumor tissue analysis e.g., tumor mutational burden, programmed cell death-ligand 1 (PD-L1) expression. Biomarkers in peripheral blood would allow a more dynamic monitoring...
Autores principales: | Meireson, Annabel, Tavernier, Simon J., Van Gassen, Sofie, Sundahl, Nora, Demeyer, Annelies, Spaas, Mathieu, Kruse, Vibeke, Ferdinande, Liesbeth, Van Dorpe, Jo, Hennart, Benjamin, Allorge, Delphine, Haerynck, Filomeen, Decaestecker, Karel, Rottey, Sylvie, Saeys, Yvan, Ost, Piet, Brochez, Lieve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198315/ https://www.ncbi.nlm.nih.gov/pubmed/34071888 http://dx.doi.org/10.3390/cancers13112630 |
Ejemplares similares
-
Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma
por: Meireson, Annabel, et al.
Publicado: (2021) -
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
por: Brochez, Lieve, et al.
Publicado: (2018) -
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
por: Sundahl, Nora, et al.
Publicado: (2017) -
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial
por: Spaas, Mathieu, et al.
Publicado: (2021) -
IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020)